Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK

Vaccine

Volumn 31, Issue 43, 2013, Pages 4961-4967

  Donegan, Katherine ^a   Beau Lejdstrom, Raphaelle ^a   King, Bridget ^a   Seabroke, Suzie ^a   Thomson, Andrew ^a   Bryan, Philip ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

Chronic fatigue syndrome; Human papillomavirus vaccine

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC FATIGUE SYNDROME; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; INCIDENCE; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED KINGDOM; VACCINATION;

CHRONIC FATIGUE SYNDROME; HUMAN PAPILLOMAVIRUS VACCINE;

ADOLESCENT; ADULT; CHILD; FATIGUE SYNDROME, CHRONIC; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; PAPILLOMAVIRUS VACCINES; RISK ASSESSMENT; YOUNG ADULT;

EID: 84885175454     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.024     Document Type: Article

References (25)

1. Accessed 17.09.12. http://www.cancerresearchuk.org/cancerinfo/cancerstats/types/cervix/mortality/.
2. McCance D.J. Papillomaviruses. Principles and Practice of Clinical Virology 2004, Wiley & Sons Ltd. 5th ed. A.J. Zuckerman, J.E. Banatvala, J.R. Pattison, P. Griffiths, B. Schoub (Eds.).
3. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-632. 10.1002/ijc.22527.
4. Accessed 2.11.12. http://www.nhs.uk/conditions/hpv-vaccination/pages/introduction.aspx?WT.mc_id=090805.
5. Annual HPV vaccine coverage in England in 2010/2011. Routine programme for school year 8 females (12-13 years old). DH HPA March 2012.
6. The 'Green Book' Chapter on Human Papillomavirus (HPV). Department of Health. Accessed 13.12.12. https://www.wp.dh.gov.uk/immunisation/files/2012/07/Green-Book-Chapter-18a-v2_0.pdf.
7. Nacul L.C., Lacerda E.M., Pheby D., Campion P., Molokhia M., Fayyaz S., et al. Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care. BMC Med 2011, 9(91). 10.1186/1741-7015-9-91.
8. Afari N., Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry 2003, 160:221-236. 10.1176/appi.ajp.160.2.221.
9. Ranjith G. Epidemiology of chronic fatigue syndrome. Occup Med 2005, 55:13-19. 10.1093/occmed/kqi012.
10. Barquet N., Domingo P., Caylà J.A. Vacination against HBV in France. Lancet 1999, 353(414.). 10.1016/S0140-6736(05)74997-7.
11. Davis S., King B., Raine J.M. Spontaneous reporting - UK. Pharmacovigilance 2007, 199-215. John Wiley & Sons Ltd., England. 2nd ed. R.D. Mann, E.B. Andrews (Eds.).
12. Gallagher A.M., Thomas J.M., Hamilton W.T., White P.D. Incidence of fatigue symptoms and diagnoses presenting in UK primary care from 1990 to 2001. J R Soc Med 2004, 97:571-575. 10.1258/jrsm.97.12.571.
13. Hamilton W.T., Gallagher A.M., Thomas J.M., White P.D. The prognosis of different fatigue diagnostic labels: a longitudinal survey. Fam Pract 2005, 22:383-388. 10.1093/fampra/cmi021.
14. Petersen I., Thomas J.M., Hamilton W.T., White P.D. Risk and predictors of fatigue after infectious mononucleosis in a large primary-care cohort. QJM 2006, 99:49-55. 10.1093/qjmed/hci149.
15. Hamilton W.T., Gallagher A.M., Thomas J.M., White P.D. Risk markers for both chronic fatigue and irritable bowel syndromes: a prospective case-control study in primary care. Psychol Med 2009, 15:1-9. 10.1017/S0033291709005601.
16. Accessed 12.07.13. http://www.connectingforhealth.nhs.uk/systemsandservices/data/uktc/readcodes.
17. Kulldorff M., Davis R.L., Kolczak M., Lewis E., Lieu T., Platt R. A maximised sequential probability ratio test for drug and vaccine safety surveillance. Sequential Anal 2011, 30:58-78. 10.1080/07474946.2011.539924.
18. Bryan P., Seabroke S., Davies C. H1N1 vaccine safety: real-time surveillance in the UK. Lancet 2010, 376:417-418.
19. Lieu T., Kulldorff M., Davis R., Lewis E., Weintraub E.S., Yih K., for the Vaccine Safety Datalink Rapid Cycle Analysis Team, et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care 2007, 45:S89-S95. 10.1097/MLR.0b013e3180616c0a.
20. Greene S., Kulldorf M., Lewis E.M., Li R., Yin R., Weintraub E.S., et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the vaccine safety datalink project. Am J Epidemiol 2010, 171:177-188. 10.1093/aje/kwp345.
21. Yih W.K., Kulldorff M., Fireman B.H., Shui I.M., Lewis E.M., Klein N.P., et al. Active surveillance for adverse events: the experience of the vaccine safety datalink project. Pediatrics 2011, 127:S54-S64. 10.1542/peds.2010-1722I.
22. Whitaker H.J., Farrington C.P., Spiessens B., Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006, 25:1768-1797. 10.1002/sim.2302.
23. National Institute for Health and Clinical Excellence: Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: NICE Guideline. Accessed 7.09.12. http://www.nice.org.uk/nicemedia/pdf/CG53NICEGuideline.pdf.
24. Accessed 26.06.13. http://www.mhra.gov.uk/Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/BlackTriangleproducts/index.htm.
25. Farrington C.P., Miller E., Taylor B. MMR and autism: further evidence against a causal association. Vaccine 2001, 19:3632-3635. 10.1016/S0264-410X(01)00097-4.